Gilteritinib is a potent Fms-like tyrosine kinase 3 (FLT3) and AXL inhibitor (IC50 = 0.29 nM and 0.73 nM, for FLT3 and AXL, respectively). In vivo, Gilteritinib reduces tumor growth and improves survival in xenograft and intra-bone marrow transplantation models of FLT3 mutated acute myeloid leukemia. Gilteritinib is orally bioavailable.
- Nom chimique ou matériau
- 6-Ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide
- CAS
- 1254053-43-4
- Quantité
- 10 mg
- Cible
- Flt-3/Flk-2/CD135
- Formule moléculaire
- C29H44N8O3
- Pureté
- 0.98
